ArticleFrontiers in cell and developmental biology2025
STC2 promotes anoikis resistance by modulating TGIF1 mRNA stability in colorectal cancer.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anoikis in cancer: molecular mechanisms, resistance, and therapeutic strategies.Apoptosis : an international journal on programmed cell death · 2026Review
- A Hypoxia Associated STC2 High Endothelial Subpopulation is Linked to Lipid Metabolic Reprogramming, Pathological Angiogenesis, and Immune Remodeling in Head and Neck Squamous Cell Carcinoma.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stanniocalcin-2 (STC2), a glycosylated protein originally identified in the endocrine glands of fish, plays multiple biological roles in cancer. However, its functional significance and molecular mechanisms in colorectal cancer (CRC) remain unclear. Methods: Bioinformatic analyses and CRC tissue specimens were used to determine STC2 expression and its prognostic value. The biological effects of STC2 on CRC cells were assessed using flow cytometry and live/dead staining assays. The underlying mechanisms were further explored by RNA sequencing, RNA immunoprecipitation (RIP), and RNA stability assays. Results: STC2 was significantly upregulated in CRC tissues and cell lines, and its high expression was associated with poor prognosis in CRC patients. Functional experiments demonstrated that STC2 enhanced CRC cell resistance to anoikis by upregulating TGIF1 expression. Mechanistically, STC2 bound to TGIF1 mRNA and stabilized it by inhibiting its degradation. Conclusion: Our findings suggest that STC2 promotes anoikis resistance in CRC by regulating TGIF1 mRNA stability. STC2 may serve as a potential therapeutic target and prognostic biomarker for colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.